Literature DB >> 411104

Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.

M L Lepow, I Goldschneider, R Gold, M Randolph, E C Gotschlich.   

Abstract

Persistence of antibody following immunization with groups A and C meningococcal polysaccharides was studied in two groups of children. Cohort 1 (20 children, 2 to 11 years of age) received two doses of A vaccine three years apart; cohort 2 (1,345 children, 6 to 8 years of age) received A or C vaccine initially and the heterologous vaccine one year later. No significant reactions were observed. Geometric mean anti-A concentrations one month after primary and booster immunization in cohort 1 were 8.77 and 13.08 microgram/ml, respectively. Mean anti-A concentration declined 32% one year after booster immunization, but then stabilized. Mean anti-A and anti-C concentrations in cohort 2 were 9.35 and 9.12 microgram/ml, respectively, one month after primary immunization. Mean anti-A concentration declined to 5.54 and 3.62 microgram/ml while anti-C levels fell to 2.35 and 1.47 microgram/ml one and four years after immunization. The proportion of children in cohort 2 with greater than or equal to 2.0 microgram/ml of anti-A and anti-C four years after immunization were 80% and 40%, respectively. An antibody concentration greater than or equal to 2.0 microgram/ml has been associated with protection against meningococcal disease. The results suggest that routine immunization of young infants with group A vaccine may result in long-lasting immunity. The usefulness of the presently available group C vaccine appears to be limited to the control of epidemics.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 411104

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009.

Authors:  Jianwei Zhou; Frances Jamieson; Sharon Dolman; Linda Mn Hoang; Prasad Rawte; Raymond Sw Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Preventative strategies on meningococcal disease.

Authors:  R T Mayon-White; P T Heath
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

4.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

5.  Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.

Authors:  L A Jackson; A Schuchat; R D Gorsky; J D Wenger
Journal:  Am J Public Health       Date:  1995-06       Impact factor: 9.308

6.  Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.

Authors:  E C Beuvery; F Miedema; R van Delft; J Haverkamp
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 9.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

Review 10.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.